Determination of the maximal tumor/normal skin ratio after HpD or m-THPC administration in hairless mouse (SKh-1) by fluorescence spectroscopy--a non-invasive method

• Published in: Anti-cancer drugs Vol. 8; no. 1; p. 67
• Main Authors: Bossu, E, A'Amar, O, Parache, R M, Notter, D, Labrude, P, Vigneron, C, Guillemin, F
• Format: Journal Article
• Language: English
• Published: England 01.01.1997
• Subjects: Animals; Antineoplastic Agents - pharmacokinetics; Antineoplastic Agents - therapeutic use; Female; Hematoporphyrin Derivative - pharmacokinetics; Hematoporphyrin Derivative - therapeutic use; Mesoporphyrins - pharmacokinetics; Mesoporphyrins - therapeutic use; Mice; Mice, Hairless; Neoplasm Transplantation; Papilloma - drug therapy; Papilloma - pathology; Photochemotherapy; Skin - pathology; Skin Neoplasms - drug therapy; Skin Neoplasms - pathology; Spectrometry, Fluorescence
• ISSN: 0959-4973
• DOI: 10.1097/00001813-199701000-00009

Two major steps in our study on the treatment of skin tumors by photochemotherapy (PCT) were the development of a skin tumor model in hairless mice by chemical carcinogenesis and by the use fluorescence spectroscopy, a semi-quantitative and non-invasive method, to determine the time after i.p. injection of photosensitizer when the tumor/normal skin ratio is the highest. Carcinogenesis provided mice bearing many benign papillomas and these were used to determine the tumor/normal skin ratios of two photosensitizers by fluorescence spectroscopy. Hematoporphyrin derivative (HpD) (5 mg/kg body weight) and m-tetra(hydroxyphenyl)-chlorin (m-THPC) (0.3 mg/kg body weight) were injected, and fluorescence measured at 4, 8, 24, 48, 72 and 96 h after injection. The tumor/normal skin ratio was 6.2 for HpD and 5.1 for m-THPC. The times required to reach these ratios were 48 h for HpD and 72 h for m-THPC. Published reports indicate that m-THPC gives a much higher tumor/normal skin ratio than HpD. These results must be confirmed by organic extraction. Photodynamic therapy with the same doses of HpD and m-THPC used in this pharmacokinetic study must also be carried out to compare the toxicities of the two photosensitizers and to determine which is best for this type of tumor.